CURE FOR HEPATITIS C VIRUS COMMON IN CKD & DIALYSIS PATIENTS SHOULD BE SOON AVAILABLE

 Kidney Transplant Centers are considering transplanting Hepatitis C Virus infected kidneys into non-infected patients to cut Kidney Transplant List waiting times. Hence, Chronic Kidney Disease and Dialysis patients are constantly exposed to the Hepatitis C Virus with very little defense because current Hepatitis C breakthrough drugs have not been approved for Chronic Kidney Disease and Dialysis patients.

Now, however, the Food and Drug Administration (FDA) granted the drug manufacturer, Merck & Co., Breakthrough Status for its Grazoprevir/Elbasvir combination medication for treatment of the Hepatitis C Virus in Chronic Kidney Disease and Dialysis patients. Results are in from the third trial phase and the Large Drug Company released results showing a 99% success rate of its combination "medication cocktail." SOURCE: KIDNEYBUZZ